Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model
Koushi Oh(Hyogo Medical University), Jiro Fujimoto(Harvard University), Takayuki Matsumoto(Kyushu University of Medical Science), Tsuyoshi Iwasaki(Sumitomo Chemical (Japan)), Kenji Nakanishi(Japan Science and Technology Agency), Yasufumi Kaneda(Osaka University), Yuji Iimuro(Yamanashi Prefectural Central Hospital), Masaharu Takeuchi(Hyogo Medical University), Nobuyuki Terada(Osaka Medical Center for Cancer and Cardiovascular Diseases)
American Journal of Physiology-Gastrointestinal and Liver Physiology
November 19, 2004
Cited by 32
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588
Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system
|International Immunology|2008|480
NFkappaB prevents apoptosis and liver dysfunction during liver regeneration.
|Journal of Clinical Investigation|1998|454
SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
|Gastrointestinal Endoscopy|2015|408